Cp*<sub>2</sub>TiMe<sub>2</sub>: An Improved Catalyst for the Intermolecular Addition of <i>n</i>-Alkyl- and Benzylamines to Alkynes
作者:Andreas Heutling、Sven Doye
DOI:10.1021/jo016311p
日期:2002.3.1
Cp*2TiMe2 has been found to be a competent catalyst for the intermolecular addition of sterically less demanding n-alkyl- and benzylamines to internal alkynes. In the presence of 2.0-6.0 mol % of the catalyst, hydroamination reactions between n-propyl-, n-hexyl-, benzyl-, p-methoxybenzyl- or 2-phenylethylamine and diphenylacetylene, 3-hexyne or 4-octyne go to completion within 24 h or less at 114 degreesC (oil bath temperature). After subsequent reduction of the initially formed imines with zinc-modified sodium cyanoborohydride in MeOH at 25 degreesC, the corresponding secondary amines can be isolated in excellent yields (>78%). Hydroamination/reduction sequences employing the unsymmetrically substituted alkyne 1-phenylpropyne give access to mixtures of regioisomeric secondary amines. The observed regioselectivity is low.
SIGMA RECEPTOR LIGANDS AND THE USE THEREOF
申请人:VIRGINIA COMMONWEALTH UNIVERSITY
公开号:EP0507863A1
公开(公告)日:1992-10-14
EP0507863A4
申请人:——
公开号:EP0507863A4
公开(公告)日:1993-07-07
US6057371A
申请人:——
公开号:US6057371A
公开(公告)日:2000-05-02
[EN] SIGMA RECEPTOR LIGANDS AND THE USE THEREOF
申请人:——
公开号:WO1991009594A1
公开(公告)日:1991-07-11
[EN] The invention relates to methods for the treatment of schizophrenia or other psychoses by administering a pharmaceutical composition comprising an effective amount of certain sigma receptor ligands to a patient in need of such treatment. The invention further relates to novel sigma receptor ligands having high binding to the sigma receptor and pharmaceutical compositions thereof. [FR] Procédés de traitement de la schizophrénie ou d'autres psychoses, par administration d'une composition pharmaceutique comprenant une quantité efficace de certains ligands de récepteur sigma, à un patient nécessitant un tel traitement. L'invention concerne également de nouveaux ligands de récepteur sigma, présentant une liaison élevée aux récepteurs sigma, ainsi que leurs compositions pharmaceutiques.